WilmerHale Counsels Syros Pharmaceuticals in $35M Private Placement

WilmerHale Counsels Syros Pharmaceuticals in $35M Private Placement

News

Syros Pharmaceuticals, a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, announced that it has entered into a stock purchase agreement with several institutional accredited investors for the private placement of 2,592,591 shares of common stock at a purchase price of $13.50 per share, yielding expected gross proceeds of $35 million.

The WilmerHale team counseling Syros included Steven Singer, Cynthia Mazareas, Mhairi Immermann, and Killian Nolan.

Read Syros Pharmaceuticals' press release for more information.